BioLine Tumbles Most on Record After Drug Fails in Study

BioLineRx Ltd. tumbled the most on record after an experimental treatment for schizophrenia failed to help patients in a mid-stage clinical trial, prompting the Israeli drugmaker to end development of the compound.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.